Background illustration for clinical trials search

Paid Clinical Trials Brockton

Discover 3,069 paid clinical trials in Brockton, Massachusetts. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2

HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease

for
Cirrhosis, End Stage Liver DIsease, Liver Cirrhosis,
Location: Boston MA
Sponsor: Massachusetts General Hospital

Sex: All

Age: 18+

Code: NCT05205954

Recruiting

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

for
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer,
Location: Boston MA, New York NY, Ottawa, Washington D.C. DC,
Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT06586515

Phase1, Recruiting

Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

for
T-Cell Large Granular Lymphocyte Leukemia
Location: Boston MA, New York NY, Columbus OH
Sponsor: Jonathan Brammer

Sex: All

Age: 18+

Code: NCT05592015

Phase2, Recruiting

Groceries for Residents of Southeastern USA to Stop Hypertension

for
Hypertension, Elevated Blood Pressure, Cardiovascular Diseases,
Location: Boston MA
Sponsor: Beth Israel Deaconess Medical Center

Sex: All

Age: 18+

Code: NCT06891911

Recruiting

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

for
Multiple Myeloma, Myeloma, Myeloma Multiple
Location: Boston MA, New York NY, Hackensack NJ, Philadelphia PA,
Sponsor: K36 Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT05651932

Phase1, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

for
Endometrial Cancer
Location: Boston MA, Providence RI, Scarborough ME, New Haven CT,
Sponsor: Merck Sharp & Dohme LLC

Sex: Female

Age: 18+

Code: NCT06952504

Phase3, Recruiting

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

for
Gastric Cancer, Gastroesophageal Junction Cancer
Location: Boston MA, The Bronx NY, New York NY, Hershey PA,
Sponsor: Daiichi Sankyo

Sex: All

Age: 18+

Code: NCT06731478

Phase3, Recruiting

SPYRAL GEMINI Pilot Study

for
Hypertension, Vascular Diseases, Cardiovascular Diseases,
Location: Boston MA, Camden NJ, Chapel Hill NC, Southfield MI,
Sponsor: Medtronic Vascular

Sex: All

Age: 18 - 70+

Code: NCT06907147

Recruiting

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

for
Small Cell Lung Cancer
Location: Boston MA, Hackensack NJ, Buffalo NY, Chicago IL,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06780137

Phase1, Phase2, Recruiting

Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3

for
COPD, Emphysema
Location: Boston MA, Philadelphia PA, Falls Church VA, DuBois PA,
Sponsor: Apreo Health, Inc.

Sex: All

Age: 40 - 70+

Code: NCT06891755

Recruiting

The Million Anesthesia Cases Study (MACS) - a Cohort Study of Preoperative Fasting and Perioperative Outcomes

for
Anesthesia, Sedation, Monitored Anesthesia Care, Procedure,
Location: Boston MA
Sponsor: Massachusetts General Hospital

Sex: All

Age: 0+

Code: NCT07022951

Recruiting

Validation of Chlamydia Diagnostic Codes in TriNetX US EHR Data

for
Chlamydial Infections
Location: Worcester MA
Sponsor: Sanofi

Sex: All

Age: 14 - 44

Code: NCT07094373

Recruiting

Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer

for
Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma
Location: Boston MA
Sponsor: Dana-Farber Cancer Institute

Sex: Female

Age: 18+

Code: NCT06543537

Recruiting

Circulating Tumor DNA

for
ER+ Breast Cancer
Location: Boston MA, New Haven CT, The Bronx NY, Baltimore MD,
Sponsor: Yale University

Sex: All

Age: 18+

Code: NCT06923527

Phase2, Recruiting

A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma

for
Cutaneous T Cell Lymphoma, Peripheral T Cell Lymphoma
Location: Boston MA
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18+

Code: NCT04045470

Recruiting

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

for
Atopic Dermatitis
Location: Brighton MA, Portsmouth NH, Brooklyn NY, Montreal,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 18 - 70+

Code: NCT06947993

Phase2, Recruiting

TrialNet Pathway to Prevention of T1D

for
Diabetes Mellitus, Type 1
Location: Boston MA, New Haven CT, New York NY, Toronto,
Sponsor: University of South Florida

Sex: All

Age: 2 - 45

Code: NCT00097292

Recruiting

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

for
Lymphoma, Large B-Cell, Diffuse
Location: Boston MA, Westbury NY, Mineola NY, Paramus NJ,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06890884

Phase2, Recruiting

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

for
Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer,
Location: Boston MA, New York NY, Philadelphia PA, Baltimore MD,
Sponsor: Verastem, Inc.

Sex: All

Age: 18+

Code: NCT07020221

Phase1, Phase2, Recruiting

Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC

for
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer,
Location: Boston MA
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18+

Code: NCT05726370

Phase2, Recruiting